

SAFETY INSPECTION REPORT AND COMPLIANCE INSPECTION

1. LICENSEE/LOCATION INSPECTED: Missouri Cancer Associates 1705 East Broadway Columbia, Missouri 65201 REPORT NUMBER(S) 2012-001		2. NRC/REGIONAL OFFICE Region III U. S. Nuclear Regulatory Commission 2443 Warrenville Road, Suite 210 Lisle, IL 60532-4352	
3. DOCKET NUMBER(S) 030-37082	4. LICENSE NUMBER(S) 24-32604-01	5. DATE(S) OF INSPECTION May 23, 2012	

LICENSEE:

The inspection was an examination of the activities conducted under your license as they relate to radiation safety and to compliance with the Nuclear Regulatory Commission (NRC) rules and regulations and the conditions of your license. The inspection consisted of selective examinations of procedures and representative records, interviews with personnel, and observations by the inspector. The inspection findings are as follows:



- 1. Based on the inspection findings, no violations were identified.
- 2. Previous violation(s) closed. (10-01)
- 3. The violation(s), specifically described to you by the inspector as non-cited violations, are not being cited because they were self-identified, non-repetitive, and corrective action was or is being taken, and the remaining criteria in the NRC Enforcement Policy, to exercise discretion, were satisfied.

Non-cited violation(s) were discussed involving the following requirement(s):

- 4. During this inspection, certain of your activities, as described below and/or attached, were in violation of NRC requirements and are being cited in accordance with NRC Enforcement Policy. This form is a NOTICE OF VIOLATION, which may be subject to posting in accordance with 10 CFR 19.11.
(Violations and Corrective Actions)

Statement of Corrective Actions

I hereby state that, within 30 days, the actions described by me to the Inspector will be taken to correct the violations identified. This statement of corrective actions is made in accordance with the requirements of 10 CFR 2.201 (corrective steps already taken, corrective steps which will be taken, date when full compliance will be achieved). I understand that no further written response to NRC will be required, unless specifically requested.

TITLE	PRINTED NAME	SIGNATURE	DATE
LICENSEE'S REPRESENTATIVE			
NRC INSPECTOR	Geoffrey M. Warren		5/23/12
BRANCH CHIEF	Tamara E. Bloomer		6/8/12

Docket File Information
SAFETY INSPECTION REPORT AND COMPLIANCE INSPECTION

1. LICENSEE/LOCATION INSPECTED: Missouri Cancer Associates 1705 East Broadway Columbia, Missouri 65201 REPORT NUMBER(S) 2012-001	2. NRC/REGIONAL OFFICE Region III U. S. Nuclear Regulatory Commission 2443 Warrenville Road, Suite 210 Lisle, IL 60532-4352
--	---

3. DOCKET NUMBER(S) 030-37082	4. LICENSE NUMBER(S) 24-32604-01	5. DATE(S) OF INSPECTION May 23, 2012
--------------------------------------	---	--

6. INSPECTION PROCEDURES USED 87132, 87131	7. INSPECTION FOCUS AREAS 03.01 - 03.07; 03.01 - 03.07
---	---

SUPPLEMENTAL INSPECTION INFORMATION

1. PROGRAM CODE(S) 02230	2. PRIORITY 2	3. LICENSEE CONTACT Iris Ouyang, M.S., RSO	4. TELEPHONE NUMBER (573) 442-5525
---------------------------------	----------------------	---	---

Main Office Inspection Next Inspection Date: May 2014

Field Office Inspection _____

Temporary Job Site Inspection _____

PROGRAM SCOPE

The licensee was a cancer treatment clinic located in Columbia, Missouri, with authorization to use iridium-192 in a High Dose Rate remote afterloader unit (HDR), strontium-90 under 35.400, and byproduct materials in Sections 35.200 and 35.300. Licensed activities were conducted only at the facility identified on the license.

The radiation therapy department was staffed with two physician authorized users, two medical physicists, and two dosimetrists. The radiation therapy staff performed 40 HDR fractions monthly. The licensee possessed a strontium-90 eye applicator which had not been used since before the previous inspection; the device would be calibrated and personnel would be trained in its use before using the device. One physicist had not yet been authorized on the license; he worked only under the supervision of an authorized medical physicist.

The nuclear medicine department was staffed with one full-time nuclear medicine technologist who administered 100 fluorine-18 FDG doses monthly for cancer imaging. In addition, the technologist administered occasional therapeutic doses of yttrium-90. Doses were received as unit doses from a licensed radiopharmacy.

Performance Observations

The inspector observed two HDR treatments, including plan verification and supervision. Licensee personnel demonstrated daily HDR unit checks, survey meter and well counter QC, contamination surveys, package receipt surveys, and dose calibrator constancy, and described HDR planning, administration of PET doses, and administration of radiopharmaceutical therapy doses. The inspector noted no concerns with these activities. The inspector reviewed written directives for HDR treatments and radiopharmaceutical therapies, and identified no concerns. Interviews with licensee personnel indicated adequate knowledge of radiation safety concepts and procedures. Dosimetry records indicated no exposures of concern to radiation workers or public. Independent and confirmatory radiation measurements indicated results consistent with licensee survey records and postings.

The inspector closed a violation cited during the previous inspection; the licensee had placed a switch so that the HDR unit and the x-ray machine in the room could not be used at the same time, as described in their response..

K91